Integrating science-backed, non-prescription active ingredients into your clinical algorithms
Pharmaceuticals and procedures are the backbone of acne treatment, but over-the-counter (OTC) skincare is playing an increasingly critical role. To bridge the gap between commercial skincare trends and medical precision, a milestone consensus paper in the Journal of Drugs in Dermatology (JDD) introduced the term “Acneceuticals.”
Coined in early 2025 by a Delphi panel of expert dermatologists, acneceuticals defines a distinct category of FDA-monographed, non-prescription active ingredients proven to safely target acne pathophysiology.
These evidence-based actives are scientifically vetted to address the four pathogenic pillars of acne: hyperkeratinization, sebum production, C. acnes, and inflammation. By pairing these barrier-repair acneceuticals with aggressive prescription topicals, clinicians can mitigate irritation, reduce transepidermal water loss (TEWL), and drastically optimize patient adherence. Ultimately, this approach provides a highly tolerable framework for long-term maintenance while actively reducing antibiotic resistance risks.
Stop letting patients navigate viral internet skincare alone. Empower your practice with peer-reviewed data to stratify these non-prescription ingredients by skin phenotype.
Explore the articles below and join the conversation.
An Algorithm Integrating Acneceuticals Into the Management of Acne Vulgaris
An Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris
Blog write-up assisted by AI
